about
Long acting systemic HIV pre-exposure prophylaxis: an examination of the field.Development and evaluation of a simple and effective RT-qPCR inhibitory assay for detection of the efficacy of compounds towards HIV reverse transcriptase.HIV prevalence and behavioral and psychosocial factors among transgender women and cisgender men who have sex with men in 8 African countries: A cross-sectional analysis.Multimodal Theranostic Nanoformulations Permit Magnetic Resonance Bioimaging of Antiretroviral Drug Particle Tissue-Cell Biodistribution.Creation of a long-acting nanoformulated dolutegravir.Emerging reverse transcriptase inhibitors for HIV-1 infection.Optimizing the preparation and stability of decorated antiretroviral drug nanocrystals.
P2860
Q39371494-6DFEA644-534A-4901-B6B5-807530C00453Q41927550-8572727C-D229-4CF6-823D-AE77919E68ABQ43923864-3F0AE665-B4AB-4B04-8D9E-DD1F38937F48Q47095093-0CBC6743-33BC-4962-A345-1956DAE39C4BQ50051618-F8EBC436-DA0F-4B6D-8880-FBD421CA3920Q53686168-18AF3CDC-85B3-40F4-BCAF-DB423BC2DE9FQ54253541-D2593E4C-AF3F-485A-AF42-422130538BF5
P2860
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh
2017年學術文章
@zh-hant
name
Long-Acting Antiretrovirals: Where Are We now?
@en
type
label
Long-Acting Antiretrovirals: Where Are We now?
@en
prefLabel
Long-Acting Antiretrovirals: Where Are We now?
@en
P2093
P2860
P1476
Long-Acting Antiretrovirals: Where Are We now?
@en
P2093
Amesika N Nyaku
Babafemi O Taiwo
Sean G Kelly
P2860
P2888
P356
10.1007/S11904-017-0353-0
P577
2017-03-16T00:00:00Z